CLINICAL TRIAL: PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 这项研究的主要目标是： 为了确定在所描述的剂量递增方案中是否达到剂量限制毒性(DLT)，使用从恶性胶质瘤患者的外周血前体中获取的自体树突状细胞皮内注射，并与从手术组织中提取的肿瘤裂解物脉冲(共培养)。如果达到DLT，则将定义最大耐受剂量(MTD)。 这项研究的次要目标是： 目的：监测注射肿瘤裂解物冲击的树突状细胞的脑肿瘤患者的生存、肿瘤进展和细胞免疫反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: The primary objective of the study is: To determine if Dose Limiting Toxicity (DLT) is reached in the dose escalation scheme described, using intradermal injections of autologous dendritic cells harvested from peripheral blood precursors and pulsed (co-cultured) with tumor lysate taken from surgical tissues in patients with malignant gliomas. If DLT is reached, then Maximum tolerated Dose (MTD) will be defined. Secondary objectives of this study are: To monitor survival, tumor progression and cellular immune responses in brain tumor patients injected with tumor lysate-pulsed dendritic cells.